The anti-IL-25 antibody-conjugated liposomes have demonstrated a remarkable ability to selectively target and induce cytotoxic effects in glioma cells, showcasing their promise as a therapeutic option for this aggressive form of brain tumor. By leveraging the unique properties of liposomes, these conjugated agents can encapsulate therapeutic drugs and deliver them directly to the tumor site, thereby minimizing systemic side effects and maximizing treatment efficacy. This targeted delivery approach not only improves the effectiveness of the therapy but also opens up new avenues for personalized medicine in the management of glioma, offering hope for improved patient outcomes.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-565 | Recombinant Anti-human IL25 Antibody | WB, ELISA, IHC, FuncS | IgG |
MOB-0231CT | Recombinant Mouse anti-Human IL25 Monoclonal antibody (79D2040) | WB | |
HPAB-AP694-YC | Human Anti-IL25 Recombinant Antibody (HPAB-AP694-YC) | ELISA | Chimeric (mouse/human) IgG |
HPAB-AP695-YC | Human Anti-IL25 Recombinant Antibody (HPAB-AP695-YC) | ELISA | Humanized (mouse/human) IgG |
HPAB-AP696-YC | Human Anti-IL25 Recombinant Antibody (HPAB-AP696-YC) | ELISA, FuncS | Humanized (mouse/human) IgG |
There are currently no Customer reviews or questions for VS-1024-FY108. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.